Using 10 mg/kg pembrolizumab every 2 weeks for up to 24 months in PD‐L1 positive metastatic pre‐treated cervical cancer, the ORR was 17% (95% confidence interval [CI] 5–37) with a disease‐control rate (DCR) of 30%. The gene discussed is CD274; the disease is cervical carcinoma.